Chemotherapy effect of Fe3O4 magnetic nanoparticles/CD/5-FU gene therapy system on U251 cells
AIM: To evaluate the feasibility of using Fe3O4 magnetic nanoparticles(Fe3O4 MNP) as cytosine deaminase gene carrier for glioma gene therapy in vitro. METHODS: Fe3O4 MNP were prepared by thermal decomposition of Fe (acac)3 in 2-pyrrolidone and 3-aminopropyltriethoxy-silane (APTTS) was used to modify the surface of the nanoparticles. Transfection was determined by delivering CD gene to gliobastoma cell line U251 using Fe3O4 MNP as gene vector. The mRNA and protein expres-sions of intracellular CD gene were tested by RT-PCR, Western blotting and Immunofluoresecnt staining, respectively. Methyl thiazolyl tetrazolium(MTT) method was used to detect the prolif-eration of U251 cells in the presence of 5-FC. RESULTS: The diameter of Fe3O4 MNP was(10±2) nm. Trausfection efficiency was (67.35±11.19)% in Fe3O4 MNP group, higher than (39.23±12.12) % in lipesome group(P<0.01). The results of RT-PCR, Western blotting and immunofluorescent staining revealed that the intracellular CD gene levels continuously in-creased in a time-dependent manner after transfection of U251 cells with Fe3O4 MNP-pCMVCD complex. CONCLUSION: Fe3O4 MNP can be used as one of the ideal gene carders for CD gene delivery and offers a basis for gene delivery in vivo. Fe3O4 MNP/CD/5-FC system can serve as brain glioma adjunctive therapy.
Fe3O4 magnetic nanoparticlegenetic carriercyto-sine deaminesegliomachemotherapy
NETL
NSTL
万方数据
维普
